Lonza Group (LONN) Investor update (Q&A) summary
Event summary combining transcript, slides, and related documents.
Investor update (Q&A) summary
8 Jul, 2026Strategic transformation and divestments
Divestment of 60% of Capsules & Health Ingredients (CHI) business to Lone Star Funds, with CHF 1.7 billion upfront and a 40% retained stake, marks the final major step in the transformation to a pure-play CDMO, completing four divestments in under two years.
CHI divestment valued at CHF 2.3 billion enterprise value, with total expected proceeds at or above CHF 3 billion at full exit.
Additional divestments include Personalized Medicines (Cocoon® Platform), MODA® software, and the Monteggio micronization site, streamlining the portfolio.
Transaction structured to provide significant immediate liquidity and future value creation potential, with preferential participation rights in value creation from the retained stake.
Estimated CHF 1.3 billion non-cash impairment to be booked in FY2025, with no impact on CDMO financials.
Financial impact and capital allocation
CHF 500 million share buyback planned post-closing, with remaining proceeds allocated to organic growth, bolt-on M&A, and maintaining a BBB+ credit rating.
Upfront proceeds to fund organic growth and acquisitions aligned with the One Lonza Strategy.
Commitment to progressive dividend policy and maintaining investment grade credit profile.
Leverage expected to be materially below target levels due to proceeds and moderated capex.
Retained CHI interest will be accounted for as an investment in an associated company.
Growth strategy and market positioning
Focused on high-value organic growth and targeted acquisitions, with CHF 7 billion planned investment in organic growth by 2030.
Strategic priorities include expanding integrated biologics, advanced synthesis, and specialized modalities.
U.S. remains a priority for future investments, with recent successful integration of a major biologics site in California.
Now operates solely in fast-growing pharmaceutical market segments, with a focus on CDMO services and three integrated CDMO business platforms powered by the Lonza Engine®.
Addressable CDMO market estimated at ~USD 100 billion, growing at 8-10% CAGR through 2030.
Latest events from Lonza Group
- H1 2026 sales rose 16% at CER, CORE EBITDA margin hit 34.8%, and the 2026 outlook was raised.LONN
H1 202622 Jul 2026 - H1 2024 delivered robust sales and EBITDA, with Vacaville set to double mammalian capacity.LONN
H1 20249 Jul 2026 - 2025 CDMO sales growth to approach 20%, with core EBITDA margin nearing 30%.LONN
Investor Update9 Jul 2026 - Flat sales, strong CDMO, US expansion, and CHI exit drive strategic transformation.LONN
H2 20248 Jul 2026 - 2024 outlook confirmed; CDMO strong, CHI and BioScience lag, CapEx below plan, major projects advance.LONN
Q3 2024 TU8 Jul 2026 - Strong Q1, reaffirmed 2026 outlook, CHI divestment, and robust CDMO demand drive momentum.LONN
Q1 2026 TU9 May 2026 - CHF 3bn+ from CHI divestment, fueling CDMO growth, buybacks, and margin expansion.LONN
Investor update28 Apr 2026 - Sales up 21.7% to CHF 6.5B, margin 31.6%, 2026 growth guided at 11%-12%, dividend up 25%.LONN
H2 20253 Feb 2026 - Unified strategy, U.S. expansion, and operational overhaul drive strong CDMO growth in 2025.LONN
44th Annual J.P. Morgan Healthcare Conference26 Jan 2026